chr10-87965321-C-T
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PP2PM2_SupportingBS3_SupportingBP4
This summary comes from the ClinGen Evidence Repository: PTEN c.1061C>T (p.Pro354Leu) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0). Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PM2_P: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533).PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.BS3_P: Well-established functional studies show no deleterious effect: Phosphatase activity >0 (score = 0.1615) per Mighell et al. 2018 (PMID:29706350).BP4: REVEL score < 0.5 (score=0.402)Using the Bayesian point system (PMID:29300386) for this variant with conflicting evidence: 2 benign supporting and 2 pathogenic supporting codes get -1*2 + 1*2 points, total is 0 (VUS). LINK:https://erepo.genome.network/evrepo/ui/classification/CA000277/MONDO:0017623/003
Frequency
Consequence
NM_000314.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PTEN | NM_000314.8 | c.1061C>T | p.Pro354Leu | missense_variant | 9/9 | ENST00000371953.8 | NP_000305.3 | |
PTEN | NM_001304717.5 | c.1580C>T | p.Pro527Leu | missense_variant | 10/10 | NP_001291646.4 | ||
PTEN | NM_001304718.2 | c.470C>T | p.Pro157Leu | missense_variant | 9/9 | NP_001291647.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PTEN | ENST00000371953.8 | c.1061C>T | p.Pro354Leu | missense_variant | 9/9 | 1 | NM_000314.8 | ENSP00000361021 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 152018Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000817 AC: 2AN: 244884Hom.: 0 AF XY: 0.00000756 AC XY: 1AN XY: 132270
GnomAD4 exome AF: 0.00000823 AC: 12AN: 1457492Hom.: 0 Cov.: 33 AF XY: 0.00000828 AC XY: 6AN XY: 724668
GnomAD4 genome AF: 0.00000658 AC: 1AN: 152018Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74252
ClinVar
Submissions by phenotype
Cowden syndrome 1 Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Apr 05, 2023 | This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Aug 04, 2017 | - - |
PTEN hamartoma tumor syndrome Uncertain:2
Uncertain significance, reviewed by expert panel | curation | Clingen PTEN Variant Curation Expert Panel, Clingen | Oct 11, 2023 | PTEN c.1061C>T (p.Pro354Leu) is currently classified as a variant of uncertain significance for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (ACMG Classification Rules Specified for PTEN Variant Curation version 3.0.0). Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column). PM2_P: Present at extremely low (<0.00001, 0.001%) allele frequency in the gnomAD cohort. (PMID 27535533). PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. BS3_P: Well-established functional studies show no deleterious effect: Phosphatase activity >0 (score = 0.1615) per Mighell et al. 2018 (PMID: 29706350). BP4: REVEL score < 0.5 (score=0.402) Using the Bayesian point system (PMID: 29300386) for this variant with conflicting evidence: 2 benign supporting and 2 pathogenic supporting codes get -1*2 + 1*2 points, total is 0 (VUS). - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 29, 2023 | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 354 of the PTEN protein (p.Pro354Leu). This variant is present in population databases (rs375709098, gnomAD 0.002%). This missense change has been observed in individual(s) with breast cancer and/or glioblastoma (PMID: 21869887, 34326862). ClinVar contains an entry for this variant (Variation ID: 142212). Advanced modeling performed at Invitae incorporating data from internal and/or published experimental studies (Invitae) indicates that this missense variant is not expected to disrupt PTEN function with a negative predictive value of 95%. Experimental studies have shown that this missense change does not substantially affect PTEN function (PMID: 29706350). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Oct 12, 2020 | Not observed at a significant frequency in large population cohorts (Lek 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed in an individual with glioblastoma (Caldera 2011); A published functional study demonstrated wild type-like phosphatase activity (Mighell 2018); This variant is associated with the following publications: (PMID: 26800850, 21869887, 29706350) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Apr 18, 2015 | - - |
Hereditary cancer-predisposing syndrome Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 31, 2024 | The p.P354L variant (also known as c.1061C>T), located in coding exon 9 of the PTEN gene, results from a C to T substitution at nucleotide position 1061. The proline at codon 354 is replaced by leucine, an amino acid with similar properties. In a humanized yeast model, lipid phosphatase activity for this variant was similar to wildtype (Mighell TL et al. Am J Hum Genet, 2018 05;102:943-955). This variant demonstrated "possibly wild-type like" intracellular protein abundance on one multiplex functional assay (Matreyek KA et al. Nat Genet, 2018 Jun;50:874-882). This variant was identified in a patient diagnosed with breast cancer as part of a large Canadian cohort study of 2870 individuals (Bhai P et al. Front Genet, 2021 Jul;12:698595). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this alteration remains unclear. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Mar 17, 2022 | This missense variant replaces proline with leucine at codon 354 of the PTEN protein. In a large scale functional study of lipid phosphatase activity in yeast this variant was observed to be functional (PMID: 29706350). This variant has been reported in an individuals affected with glioma in the literature (PMID: 21869887). This variant has been identified in 2/244884 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at